New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR amyloidosis CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex ...

Group 1: Ark Invest Portfolio Strategy - Ark Invest, led by Cathie Wood, focuses on aggressive investments in growth businesses pursuing disruptive innovation [1][2] - The portfolio recently increased its holdings in two biotech stocks, indicating a belief in their potential for success despite inherent risks [1][2] Group 2: Intellia Therapeutics - Intellia Therapeutics is a gene-editing biotech aiming to treat inherited rare diseases by editing dysfunctional genes [3][4] - The company has a late-stage program for transthyretin (ATTR) amyloidosis entering phase 3 trials and a mid-stage program for hereditary angioedema (HAE) with upcoming data [4][5] - Financially, Intellia reported approximately $940 million in cash and equivalents, with R&D expenses of about $449 million, providing a runway until late 2026 [5] - Risks include potential scientific or regulatory hurdles that could significantly impact the company's value [6][7] Group 3: Recursion Pharmaceuticals - Recursion Pharmaceuticals holds a focus on using artificial intelligence (AI) in drug development, with a pipeline of therapies for rare diseases [8][9] - The company is merging with Exscientia, expected to close in early 2025, which will enhance its cash position and oncology pipeline [9][10] - The merged entity will have around $850 million in cash and is projected to achieve $100 million in efficiencies post-transaction [10] - The new company anticipates up to 10 clinical data readouts in the next 18 months, presenting potential catalysts for stock movement [10][11] - Collaborations with major biopharma companies like Merck, Roche, and Nvidia suggest confidence in Recursion's future prospects [12][13]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. Intellia Therapeutics (NASDAQ: NTLA ) is one of the vanguard of companies that is attempting to convert the amazing and Nobel Prize winning technology of CRISPR/Cas9 into ...

Intellia Therapeutics, Inc. (NTLA) incurred second-quarter 2024 loss of $1.31 per share (excluding a one-time expense of change in fair value of investments), which was wider than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago quarter, Intellia had incurred a loss of $1.40 per share. Including the above one-time expense, the company reported a loss of $1.52 per share in the second quarter of 2024. The company's total revenues currently comprise only collaboration revenues. NTLA reported re ...

Corporate Strategy & Pipeline - Intellia plans to initiate two additional in vivo Phase 3 studies in 2024[6] - Intellia expects to submit a BLA for NTLA-2002 for HAE in 2026[16] - Strategic priorities for 2024-2026 include demonstrating human proof-of-concept for targeted in vivo gene insertion and initiating clinical development for its allogeneic ex vivo program[3] NTLA-2001 (nexiguran ziclumeran) for ATTR Amyloidosis - NTLA-2001 led to a -91% change from baseline in serum TTR at day 28[34] - A Phase 3 trial is underway for ATTR-CM patients with NT-proBNP baseline ≥ 1000 pg/mL[38] - GlobalData projects an $11B+ global market size for ATTR amyloidosis by 2029[28] NTLA-2002 for Hereditary Angioedema (HAE) - NTLA-2002 demonstrated a 98% reduction in HAE attack rate, with 8 of 10 patients attack-free in the post-primary observation period[48] - NTLA-2002 continues to show dose-dependent and durable reductions in plasma kallikrein protein over time[46] - GlobalData projects a $6B+ global market size for HAE by 2029[41] NTLA-3001 for Alpha-1 Antitrypsin Deficiency (AATD) - NTLA-3001 aims to achieve normal human levels of AAT protein and halt progression of lung disease[50] - In preclinical studies, NTLA-3001 achieved durable production of physiologic levels of hAAT through one year in NHPs[51]

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.26%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.06, delivering a surprise of 21.48%. Over the last four quarters, the compan ...

Core Insights - Intellia Therapeutics reported positive results from the Phase 2 study of NTLA-2002 for hereditary angioedema, meeting all primary and secondary endpoints, and plans to advance to a pivotal Phase 3 trial with a selected 50 mg dose [1][2][3] - The company is on track to initiate multiple Phase 3 trials for NTLA-2001 and NTLA-3001 by the end of 2024, expanding its clinical pipeline [1][4][5] - Intellia ended Q2 2024 with approximately $940 million in cash, indicating a strong financial position to support ongoing and future clinical trials [1][9] Hereditary Angioedema (HAE) - NTLA-2002 demonstrated significant efficacy with a 98% mean reduction in monthly HAE attack rate and a high percentage of patients remaining attack-free for over 18 months after treatment [3] - The FDA has provided support for the Phase 3 plans following a successful end-of-Phase 2 meeting, with the trial expected to start in the second half of 2024 [2][3] Transthyretin (ATTR) Amyloidosis - NTLA-2001, now known as nexiguran ziclumeran (nex-z), is advancing rapidly in the Phase 3 MAGNITUDE trial for ATTR amyloidosis with cardiomyopathy, with regulatory approvals in over 12 countries [4] - A pivotal Phase 3 trial for hereditary ATTR amyloidosis with polyneuropathy is planned to begin by year-end 2024 [4] Alpha-1 Antitrypsin Deficiency (AATD) - NTLA-3001 is set to initiate a Phase 1/2 study in the second half of 2024, targeting AATD-associated lung disease through CRISPR-mediated gene insertion [5] Financial Performance - The company reported a net loss of $147 million for Q2 2024, compared to a loss of $124 million in Q2 2023, with total operating expenses slightly increasing year-over-year [9][16] - Collaboration revenue decreased to $7 million in Q2 2024 from $13.6 million in the same quarter of 2023, primarily due to reduced revenue from the AvenCell collaboration [9][16] Corporate Updates - Intellia appointed Brian Goff to its board of directors and Edward Dulac as Chief Financial Officer, enhancing its leadership team [8]

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...

As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks. An entrepreneur and a tech visionary, Wood is considered a star stock picker. She's the founder of ARK Invest, which features around $60 billion worth of assets. Part of the reason for considering the ideas she supports is longevity. Wood has b ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...